Australia Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Australia Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Australia Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: Reforms to Australia's drug approval process will be beneficial for both the pharmaceutical industry and for patient access to innovative medicines. In particular, the introduction of an expedited approval process will have the potential to be a paradigm shift in the market, accelerating the time taken for new active substances to be approved. Limiting these potential benefits for the industry and patients will be the tough listing process on Australia's Pharmaceutical Benefit Scheme, which continues to place a strong emphasis on cost effectiveness.

Headline Expenditure Projections

  • Pharmaceuticals : AUD13.9bn (USD10.4bn) in 2015 to AUD14.3bn (USD10.6bn) in 2016; +3.0% in local currency terms and +1.4% in US dollar terms. US dollar forecast revised due to significant exchange rate fluctuations.

  • Healthcare: AUD162.0bn (USD121.7bn) in 2015 to AUD168.9bn (USD124.9bn) in 2016; +4.3% in local currency terms and +2.6% in US dollar terms. US dollar forecast revised due to exchange rate fluctuations.

Headline Pharmaceuticals & Healthcare Forecasts (2014-2020)
2014 2015 2016f 2017f 2018f 2019f 2020f
f = BMI forecast. Source: National Sources, BMI
Pharmaceutical sales, USDbn 12.150 10.470 10.490 10.440 10.100 10.110 10.340
Pharmaceutical sales, % of GDP 0.84 0.86 0.86 0.85 0.83 0.81 0.79
Pharmaceutical sales, % of health expenditure 8.7 8.6 8.5 8.4 8.3 8.1 8.0
Health spending, USDbn 140.010 121.690 123.240 124.170 122.090 124.370 129.600

Risk/Rewards Index

In Q117 Australia remains ranked jointly with Taiwan as the second most attractive market to pharmaceutical investors in the Asia Pacific region (scoring 66.0 out of 100), after Japan (80.6). Australia's Risk/Reward Index score is driven by a relatively high drug spending per capita (scoring 7.2 out of 12), a large pensionable population (scoring 6.4 out of 8) and robust population growth (scoring 3.5 out of 5), but is dragged down by poor sector growth (sector value growth score of 0 out of 12).

Latest Updates

  • In September 2016, local news sources note that almost 70% of Australians polled with private health insurance are considering the option of dropping or downgrading their private health insurance. Almost 80% also note they believe the health insurance firms are putting profits before patients. Conducted by ReachTEL, the study also noted that the average cost of premiums has risen by 35% since 2010, outpacing inflation.

  • That same month, the government accepted some of the recommendations put forth by the Expert Panel Review of Medicines and Medical Devices Regulation. Critically, the expert panel recommended the introduction of an expedited drug approval process which will accelerate access to new medicines - a plus for the industry and patients.

  • As a result of the Pharmaceutical Benefit Scheme Access and Sustainability Package reforms passed in 2015, more than 2,000 medicine brands will see a reduction in price by as much as AUD20 (USD15) per script. This stems in part from the decision to remove originator medicine prices in the calculation.

BMI Economic View

The RBA reduced its cash rate by 25bps to 1.50% at its August 2 monetary policy meeting, and following a total of 50bps worth of cuts since May, we expect the central bank to keep its key policy rate steady for the rest of 2016 as it looks to assess the impact of its accommodative monetary policy stance. That said, we forecast the RBA to cut interest rates further by another 25bps to 1.25% by H117 as the Australian economy weakens while below-target inflation persists.

BMI Political View

Australia's Liberal-National coalition formed the government for a second term, following the July 2 federal elections, but we believe that it will not be able to significantly improve the country's business environment and economic growth prospects over the coming years. The coalition's expected lack of majority in the Senate suggests that risks of policies being delayed and diluted are high. Additionally, the coalition's narrow margin of victory against the opposition Australian Labour Party is a significant setback for Prime Minister Malcolm Turnbull, and there is an increasing possibility that his leadership position might be challenged, which would create further uncertainty for businesses.

BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (2014-2020)
7
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Australia 2012-2020)
14
Healthcare Market Forecast
15
Table: Selected Health Measures In Australia FY2015/16 Budget
16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Australia 2012-2020)
18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Australia 2012-2020)
18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Australia 2012-2020)
19
Prescription Drug Market Forecast
20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Australia 2012-2020)
22
Patented Drug Market Forecast
23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Australia 2012-2020)
25
Generic Drug Market Forecast
26
Table: Cost Of Selected Drugs Post-Price Disclosure, April 2013
28
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Australia 2012-2020)
29
OTC Medicines Market Forecast
30
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Australia 2012-2020)
32
Pharmaceutical Trade Forecast
33
Table: Pharmaceutical Trade Data And Forecasts (Australia 2014-2020)
35
Table: Pharmaceutical Trade Data And Forecasts local currency (Australia 2014-2020)
35
Industry Risk Reward Index
36
Asia Pacific Risk/Reward Index - Q3 2016
36
Australia Risk/Reward Index
42
Rewards
42
Risks
43
Regulatory Review
44
Table: EU & ICH Guidelines Adopted In The TGA's Biosimilars Guidance Document
45
Intellectual Property Issues
47
Pricing & Reimbursement Regime
51
Table: Selected Drugs Undergoing SPD (AUD)
52
Table: Historical PBS Co-Payments
53
Table: New PBS Formularies
56
Market Overview
57
Healthcare Sector
57
Research & Development
58
Clinical Trials
59
Epidemiology
60
Table: Estimated Number Of New Cases Of Cancer In Australia
63
Competitive Landscape
65
Research-Based Industry
65
Table: Multinational Market Activity
66
Pharmaceutical Distribution
67
Company Profile
69
Australian Pharmaceutical Industries
69
CSL
72
GlaxoSmithKline
76
Mayne Pharma Group
80
Sanofi
83
Sigma
86
Demographic Forecast
90
Table: Population Headline Indicators (Australia 1990-2025)
91
Table: Key Population Ratios (Australia 1990-2025)
91
Table: Urban/Rural Population & Life Expectancy (Australia 1990-2025)
92
Table: Population By Age Group (Australia 1990-2025)
92
Table: Population By Age Group % (Australia 1990-2025)
93
Glossary
95
Methodology
97
Pharmaceutical Expenditure Forecast Model
97
Healthcare Expenditure Forecast Model
97
Notes On Methodology
98
Risk/Reward Index Methodology
99
Index Overview
100
Table: Pharmaceutical Risk/Reward Index Indicators
100
Indicator Weightings
101

The Australia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Australia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Australia pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Australia, to test other views - a key input for successful budgeting and strategic business planning in the Australian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Australian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Australia.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.